27623945|t|Hint1 suppresses migration and invasion of hepatocellular carcinoma cells in vitro by modulating girdin activity
27623945|a|Histidine triad nucleotide-binding protein 1 (Hint1) is a haploinsufficient tumor suppressor gene. Its role in cancer cell migration has not been previously speculated. In the current study, we examined the expression of Hint1 in metastatic and non-metastatic lymph nodes of hepatocellular carcinoma (HCC) patients and further elucidated the effect of Hint1 expression on girdin expression and phosphorylation of AKT and ERK1 / 2 and on the migration of HCC cells in vitro. Expression of Hint1 and girdin in primary HCC tissues and metastatic and non-metastatic lymph nodes was determined by RT-PCR assays. HepG2 cells were transfected with plasmid vectors overexpressing Hint1 or small interfering RNA (siRNA) targeting Hint1, girdin, Hint1 plus girdin, or the scrambled RNA. Migration and invasion of HCC cells were examined by wound and Transwell assays. Protein expression was detected by immunofluorescence and immunoblotting assays. RT-PCR assays revealed that the messenger RNA (mRNA) transcript levels of Hint1 were markedly lower than those of primary HCC tissues and non-metastatic lymph nodes (P < 0.01). By contrast, the mRNA transcript levels of girdin were significantly higher than non-metastatic lymph nodes (P < 0.05). Furthermore, siRNA knockdown of HINT1 resulted in a significant increase in the mRNA transcript levels of girdin in HepG2 cells (P < 0.05). Wound assays and Transwell assays showed that Hint1 knockdown by siRNA significantly enhanced the migration and invasion of HepG2 cells compared to HepG2 cells transfected with scrambled siRNA. Hint1 knockdown also led to significantly increased phosphorylation of girdin and AKT in HepG2 cells (P < 0.05), which, however, was effectively aborted by girdin knockdown by siRNA (P < 0.05). Hint1 is downregulated in metastatic lymph nodes and is implicated in migration and invasion of HCC cells in vitro by modulating girdin and AKT expression and phosphorylation. The Hint1 - girdin - AKT signaling axis should be further dissected for its role in HCC migration and invasion and may be therapeutically targeted to suppress tumor growth and metastasis.
27623945	0	5	Hint1	T028	C1415545
27623945	6	16	suppresses	T169	C1260953
27623945	17	26	migration	T191	C0027627
27623945	31	39	invasion	T046	C0027626
27623945	43	67	hepatocellular carcinoma	T191	C2239176
27623945	68	73	cells	T025	C0007634
27623945	74	82	in vitro	T080	C1533691
27623945	86	96	modulating	T082	C0443264
27623945	97	103	girdin	T116,T123	C1571428
27623945	104	112	activity	T169	C0205177
27623945	113	157	Histidine triad nucleotide-binding protein 1	T028	C1415545
27623945	159	164	Hint1	T028	C1415545
27623945	171	188	haploinsufficient	T049	C2936267
27623945	189	210	tumor suppressor gene	T028	C0079427
27623945	224	245	cancer cell migration	T191	C0027627
27623945	297	302	study	T062	C2603343
27623945	307	315	examined	T033	C0332128
27623945	320	330	expression	T045	C0017262
27623945	334	339	Hint1	T028	C1415545
27623945	343	353	metastatic	T191	C0027627
27623945	358	372	non-metastatic	T191	C1334991
27623945	373	384	lymph nodes	T023	C0024204
27623945	388	412	hepatocellular carcinoma	T191	C2239176
27623945	414	417	HCC	T191	C2239176
27623945	419	427	patients	T101	C0030705
27623945	465	470	Hint1	T028	C1415545
27623945	471	481	expression	T045	C0017262
27623945	485	491	girdin	T116,T123	C1571428
27623945	492	502	expression	T045	C1171362
27623945	507	522	phosphorylation	T044	C0031715
27623945	526	529	AKT	T116,T126	C0164786
27623945	534	538	ERK1	T116,T126	C4082284
27623945	541	542	2	T116,T126	C2713871
27623945	554	563	migration	T191	C0027627
27623945	567	570	HCC	T191	C2239176
27623945	571	576	cells	T025	C0007634
27623945	577	585	in vitro	T080	C1533691
27623945	587	597	Expression	T045	C0017262
27623945	601	606	Hint1	T028	C1415545
27623945	611	617	girdin	T028	C1428495
27623945	629	632	HCC	T191	C2239176
27623945	633	640	tissues	T024	C0040300
27623945	645	655	metastatic	T191	C0027627
27623945	660	674	non-metastatic	T191	C1334991
27623945	675	686	lymph nodes	T023	C0024204
27623945	705	718	RT-PCR assays	T059	C2732732
27623945	720	731	HepG2 cells	T025	C2717940
27623945	737	748	transfected	T063	C0040669
27623945	754	769	plasmid vectors	T114	C1514152
27623945	770	784	overexpressing	T045	C1514559
27623945	785	790	Hint1	T116,T123	C1505103
27623945	794	815	small interfering RNA	T114,T123	C1099354
27623945	817	822	siRNA	T114,T123	C1099354
27623945	824	833	targeting	T044	C1159372
27623945	834	839	Hint1	T116,T123	C1505103
27623945	841	847	girdin	T116,T123	C1571428
27623945	849	854	Hint1	T116,T123	C1505103
27623945	860	866	girdin	T116,T123	C1571428
27623945	885	888	RNA	T114	C0035668
27623945	890	899	Migration	T191	C0027627
27623945	904	912	invasion	T046	C0027626
27623945	916	919	HCC	T191	C2239176
27623945	920	925	cells	T025	C0007634
27623945	931	939	examined	T033	C0332128
27623945	943	969	wound and Transwell assays	T059	C1513300
27623945	971	989	Protein expression	T045	C1171362
27623945	1006	1024	immunofluorescence	T059	C0079603
27623945	1029	1050	immunoblotting assays	T059	C0020985
27623945	1052	1065	RT-PCR assays	T059	C2732732
27623945	1084	1097	messenger RNA	T114,T123	C0035696
27623945	1099	1103	mRNA	T114,T123	C0035696
27623945	1105	1115	transcript	T114	C1519595
27623945	1126	1131	Hint1	T028	C1415545
27623945	1174	1177	HCC	T191	C2239176
27623945	1178	1185	tissues	T024	C0040300
27623945	1190	1204	non-metastatic	T191	C1334991
27623945	1205	1216	lymph nodes	T023	C0024204
27623945	1246	1250	mRNA	T114,T123	C0035696
27623945	1251	1261	transcript	T114	C1519595
27623945	1272	1278	girdin	T116,T123	C1571428
27623945	1284	1304	significantly higher	T081	C4055637
27623945	1310	1324	non-metastatic	T191	C1334991
27623945	1325	1336	lymph nodes	T023	C0024204
27623945	1362	1367	siRNA	T114,T123	C1099354
27623945	1368	1377	knockdown	T063	C2350567
27623945	1381	1386	HINT1	T028	C1415545
27623945	1401	1412	significant	T078	C0750502
27623945	1429	1433	mRNA	T114,T123	C0035696
27623945	1434	1444	transcript	T114	C1519595
27623945	1455	1461	girdin	T116,T123	C1571428
27623945	1465	1476	HepG2 cells	T025	C2717940
27623945	1489	1522	Wound assays and Transwell assays	T059	C1513300
27623945	1535	1540	Hint1	T028	C1415545
27623945	1541	1550	knockdown	T063	C2350567
27623945	1554	1559	siRNA	T114,T123	C1099354
27623945	1560	1573	significantly	T078	C0750502
27623945	1574	1582	enhanced	T052	C2349975
27623945	1587	1596	migration	T191	C0027627
27623945	1601	1609	invasion	T046	C0027626
27623945	1613	1624	HepG2 cells	T025	C2717940
27623945	1637	1648	HepG2 cells	T025	C2717940
27623945	1649	1660	transfected	T063	C0040669
27623945	1676	1681	siRNA	T114,T123	C1099354
27623945	1683	1688	Hint1	T028	C1415545
27623945	1689	1698	knockdown	T063	C2350567
27623945	1711	1724	significantly	T078	C0750502
27623945	1735	1750	phosphorylation	T044	C0031715
27623945	1754	1760	girdin	T116,T123	C1571428
27623945	1765	1768	AKT	T116,T126	C0164786
27623945	1772	1783	HepG2 cells	T025	C2717940
27623945	1828	1835	aborted	T169	C1609614
27623945	1839	1845	girdin	T028	C1428495
27623945	1846	1855	knockdown	T063	C2350567
27623945	1859	1864	siRNA	T114,T123	C1099354
27623945	1877	1882	Hint1	T028	C1415545
27623945	1886	1899	downregulated	T044	C0013081
27623945	1903	1913	metastatic	T191	C0027627
27623945	1914	1925	lymph nodes	T023	C0024204
27623945	1947	1956	migration	T191	C0027627
27623945	1961	1969	invasion	T046	C0027626
27623945	1973	1976	HCC	T191	C2239176
27623945	1977	1982	cells	T025	C0007634
27623945	1983	1991	in vitro	T080	C1533691
27623945	1995	2005	modulating	T082	C0443264
27623945	2006	2012	girdin	T116,T123	C1571428
27623945	2017	2020	AKT	T116,T126	C0164786
27623945	2021	2031	expression	T045	C1171362
27623945	2036	2051	phosphorylation	T044	C0031715
27623945	2057	2062	Hint1	T116,T123	C1505103
27623945	2065	2071	girdin	T116,T123	C1571428
27623945	2074	2077	AKT	T116,T126	C0164786
27623945	2078	2087	signaling	T038	C3537152
27623945	2111	2120	dissected	T169	C0205239
27623945	2137	2140	HCC	T191	C2239176
27623945	2141	2150	migration	T191	C0027627
27623945	2155	2163	invasion	T046	C0027626
27623945	2175	2190	therapeutically	T061	C0087111
27623945	2203	2211	suppress	T169	C1260953
27623945	2212	2224	tumor growth	T191	C0598934
27623945	2229	2239	metastasis	T191	C0027627